REALIZATION OF REPRODUCTIVE OPPORTUNITIES AND PROLONGATION OF REMISSION OF UTERINE FIBROIDS AFTER SURGICAL TREATMENT
- Authors: Apresyan S.V1,2, Dimitrova V.I1, Slyusareva O.A1, Lyubeshkina V.A1, Mustafaeva T.G1
-
Affiliations:
- City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare Department
- Peoples' Friendship University of Russia
- Issue: No 6 (2018)
- Pages: 36-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295352
- ID: 295352
Cite item
Open Access
Access granted
Abstract
Objective. Assessment of the realization of reproductive opportunities and the frequency of recurrence of the disease in patients who underwent organ-preserving treatment for uterine fibroids (UFs) and a course of adjuvant therapy with mifepristone (Gynestril) for two years after drug discontinuation. Methods. A cohort prospective comparative study included 136 women who underwent organ-preserving treatment (myomectomy or uterine artery embolization) for UFs. Mifepristone was administered at a dose of 50 mg/day (1 tablet) starting from the 1 day of the menstrual cycle after surgical treatment in a continuous mode for 3 months, taking into account contraindications to its use. Results. It was shown that the use of mifepristone in continuous mode after surgical treatment for proliferative UFs led to the absence of relapses of the disease within two years after drug discontinuation. The use of mifepristone after uterine artery embolization significantly reduced node size by 25% at 12 months and by 50% (p<0.05) at 24 months. Complex treatment of UFs, including myomectomy and drug therapy with mifepristone, allowed to realize reproductive function in 46% of patients. Conclusion. Long-term results of the study make it possible to recommend mifepristone in the postoperative period for patients who underwent organ-preserving treatment for proliferating UFs in order to prevent recurrence of the disease within 24 months after drug discontinuation.
Full Text
About the authors
S. V Apresyan
City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare Department; Peoples' Friendship University of Russia
Email: sapresyan@mail.ru
MD, Prof. at the Department of Obstetrics and Gynecology with the Course of Perinatology; Deputy Chief Physician for Obstetric and Gynecological Care Moscow, Russia
V. I Dimitrova
City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare DepartmentMoscow, Russia
O. A Slyusareva
City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare DepartmentMoscow, Russia
V. A Lyubeshkina
City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare DepartmentMoscow, Russia
T. G Mustafaeva
City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare DepartmentMoscow, Russia
References
- Хашукоева А.З., Агаева М.И., Дугиева М.З., и др. Повышение шансов наступления беременности после миомэктомии в программах ВРТ Медицинский совет. 2017;13:3-7.
- Андреева Е.Н., Рябинкина Т.С., Рыжова Т.Е. Минздрав настоятельно рекомендует. Обзор нового клинического протокола диагностики и лечения миомы матки. Status Praesens. 2016;2(31):41-50.
- Миома матки: диагностика, лечение и реабилитация: клинические рекомендации (протокол лечения). М., 2015.
- Радзинский В.Е., Тотчиев Г.Ф. Миома матки: курс на органосохранение. Информационный бюллетень. М., 2014. 24 с.
- Marsh E.E., Ekpo G.E., Cardozo E.R., et al. Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot stude. Fertil. Steril. 2013;99(7):1951-57.
- Baird D.D., Harmon Q.E., Upson K., et al. A prospective, ultrasound-based study to evaluate risk factors for uterine fibroid incidence and growth: methods and resultsof Recruitment. J. Womens Health. 2015;24(11):907-15.
- Metwally M., Cheong Y.C., Horne A.W. Surgical treatment of fibroid for subfertility. Cochrane Database Syst. Rev. 2012;11:CD003857.
- Лебедев В.А., Давыдов А.И., Пашков В.М. Спорные и нерешенные вопросы лечения и профилактики миомы матки у больных репродуктивного периода. Трудный пациент. 2013;11(8-9):14-9.
- Политова А.К. Оптимизация хирургического лечения больной миомой матки. Дисс. докт. мед. наук. М., 2014. 52 с.
- Laughlin S.K. Individualizing the approach to a heterogeneous condition. Obstet. Gynecol. Author manuscript; available in PMC.
- Baird D.T., Brown A., Critchley H.O., et al. Effect of long -term treatment with low dise mifepristone on the endometrium. Hum. Reprod. 2003;18:61-8.
- Тихомиров А.Л., Лубнин Д.М., Кочарян А.А. Современный алгоритм комплексного консервативного лечения миомы матки. Репродуктвиное здоровье женщины. 2007;9(6):13-5.
- Беженарь В.Е., Павлова Н.Г., Прохорова В.С. Возможности применения Гинестрила при неоадъювантной терапии больных репродуктивного возраста. Здоровье женщины. 2008;4:18-21.
- Eisinger S.H. Bonfiglio T., Fiscella K., et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myumas. J. Minim. Invasive Gynecol. 2005;12:227-33.
- Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing. No new patients should start treatment for the time being. European Medicines Agency.9.02.2018. EMA. 76828/2018.
- Pritts E.A., Parker W.H., Olive D.L. Fibroid and infertility:an updated systematic review of theevidence. Fertil. Steril. 2009;91(4): 1215-23.
- Rein M.S. Friedman A.J., Barbieri R.L., et al. Cytogenetic abnormalities in uterine leiomyimata. Obstet. Gynecol. 1991;77(6):923-26.
- Exavery A., Mrema S., Shamte A. Levels and correlates of non-adherence to WHO recommended inter-birth intervals in Rufiji, Tanzania. BMC Pregn. Child. 2012;12:152.
- Самойлова Т.Е. Перспективы применения мифепристона в лечении миомы матки. Информационный бюллетень. М., 2015.
Supplementary files
